Clinical Trial Update: Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update of ONTAK (denileukin diftitox) in patients with previously treated cutaneous T-cell lymphoma, including Mycosis fungoides and Seza…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Sezary Syndrome

Drugs mentioned

• ONTAK (denileukin diftitox)

Snippet

Sponsor: Eisai Inc. | Conditions: Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides | Phase 4 | Status: COMPLETED